Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 73 Publications

13 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 M4TyS2N6fG:2b4jpZ{BCe3OjeR?= MoLlNVAhdk1? M3L0PVczKGh? Mnv0SG1UVw>? M17iRXBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> M4TCO|I1QTByOEez
HT-29 NXKySllyS3m2b4TvfIlkKEG|c3H5 NX30bI5OOTBibl2= Mny3O|IhcA>? NXHFfmtMTE2VTx?= MVHQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl? MYeyOFkxODh5Mx?=
HT-29 NFPZe|BEgXSxdH;4bYMhSXO|YYm= MYGxNEBvVQ>? MWS3NkBp MVrEUXNQ NE\JXGJRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? M3\1OVI1QTByOEez
PC3 NXK2UHRRU2mwYYPlJGF{e2G7 MYOxNFAhdk1? M4XYfVEhcA>? Mn;zSG1UVw>? M4rqSXBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA9OTBibl2u NHLZTIQzOTl5OE[4Ny=>
PC3 NYfmWlJlU2mwYYPlJGF{e2G7 Mkn5NVAxKG6P Moj4NUBp MmraSG1UVw>? MoWwSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? MWCyNVk4QDZ6Mx?=
PC3 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\FNFAyNjVizszN NGHZT2MyKGh? NYPpcZBSTE2VTx?= NUXFR2cyUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N MlW2NlE6Pzh4OEO=
HEK293 MVrGeY5kfGmxbjDBd5NigQ>? MYGxNFAhdk1? NF25WZQ5KGh? NYr4d3YxTE2VTx?= NVHjb|k5UW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N NV6yPXBuOjF3M{mzNFE>
BT-20 M2PyTGtqdmG|ZTDBd5NigQ>? NGHGeXUzOCEQvF2= M4G5SmROW09? NWDxeFB[TG:nczDuc5QhcW6qaXLpeEBuXE:UQ{Kg[IVx\W6mZX70JJBCc1RiU{S3N{BxcG:|cHjvdplt[XSrb36= M{LCN|IyOzV|NUWx
U937 MmS5RY51cWKjY4TldolidCCDc4PhfS=> NVfIXohzPTBizszN Mn\EOFghcA>? M{TBTmROW09? NGjtbWJKdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N|ch[2WubIO= MoPENlEyPDJzME[=
U937 Mnu0RY51cWKjY4TldolidCCDc4PhfS=> MlfqOVAh|ryP MV20PEBp Mn\CSG1UVw>? MUDEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JG1KWCCycn;0[YlvNWSnZnnjbYVvfCCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJGpTOzJvMjDpckBWQTN5IHPlcIx{ MYiyNVE1OjFyNh?=
U937 MoT5RY51cWKjY4TldolidCCDc4PhfS=> NGrPTHk2OCEQvF2= NITUWHQ1QCCq NWPR[IVpTE2VTx?= MkKwSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM> MoDVNlEyPDJzME[=
MCF-7 MnHJRZV1d3CqYXf5JGF{e2G7 NIHTW4g{OCCwTR?= MUW0JIg> NG\VRYNFVVOR NXX2ZYI6UW6mdXPld{BifXSxcHjh[5k> MkfuNlAxOjhzM{S=
U87MG MorNT4lv[XOnIFHzd4F6 MoW5NUDPxE1? NV\zeWllPiCq MUnEUXNQ M3;venBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w NFPmV2gyQTh2OESwOC=>
U87MG M4PucWtqdmG|ZTDBd5NigQ>? M1n4NlEh|ryP NFLBe4k3KGh? NYXaTFJZTE2VTx?= NWL6V2RUWG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44> MXuxPVg1QDRyNB?=
U87MG MXLLbY5ie2ViQYPzZZk> NGjhWGkyKM7:TR?= NITpXmk3KGh? MUPEUXNQ M4LSNWRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w Mn;JNVk5PDh2MES=
U87MG MYrLbY5ie2ViQYPzZZk> MoC5NUDPxE1? M2O1b|YhcA>? NHn6coFFVVOR M32wV2Rw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN|cwPDZrIIDoc5NxcG:{eXzheIlwdg>? MoXUNVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rheb NH72e2dCfXSxcHjh[5khSXO|YYm= MnLpNE4zKM7:TR?= Mon4NlQhcA>? NEXvcYFFVVOR M4nnSmlv\HWlZYOgZZV1d3CqYXf5 MX:xPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3 NHXYd3RCfXSxcHjh[5khSXO|YYm= NVTSeWFvOC5{IN88US=> M{\qSFI1KGh? NH3URVlFVVOR MYDJcoR2[2W|IHH1eI9xcGGpeR?= Mo\hNVg{QTF7NEm=
H4 M37tPGZ2dmO2aX;uJGF{e2G7 NWmwXHdUOC5{IN88US=> NIXDTGgzPCCq NHf5eGFFVVOR NVfKPZJzUW6lcnXhd4V{KHSqZTDyZZRqdyCxZjDsbYdpfCClaHHpckA{KHO3YoXubZQhOiC2bzDsbYdpfCClaHHpckA{KHO3YoXubZQhOSCrbjDoeY1idiCKNDDj[Yxtew>? MU[xPFAzPDV6NB?=
HeLa M4PWPWZ2dmO2aX;uJGF{e2G7 MVixNFAhdk1? MV2zOkBp MVTEUXNQ NETx[5pKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v M1PjVFE4PTZ|M{i1
HeLa NGHRcJVHfW6ldHnvckBCe3OjeR?= M4fEflExOCCwTR?= M17EW|M3KGh? MUDEUXNQ NYLzcVBNUW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w Ml7INVc2PjN|OEW=
HeLa M4nocWZ2dmO2aX;uJGF{e2G7 Ml3XNVAxKG6P MXGzOkBp MYjEUXNQ M2fheGlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> NHXSUVgyPzV4M{O4OS=>
SYF MmLaSpVv[3Srb36gRZN{[Xl? NWjKbVVGOTByIH7N MmrlNlQhcA>? NILkUHdFVVOR NW\a[Fl1UW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v MoXzNVc2PjN|OEW=
SYF MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\jOYEyODBibl2= MomyNlQhcA>? NGH4RmdFVVOR M3G1Wmlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDTXWYh[2WubIO= NXvCeZhSOTd3NkOzPFU>
HEK293T MVnBcpRqfmm{YXygRZN{[Xl? NXrSe|hEOSCwTR?= MVm0JIQ> M2fuV2ROW09? NGO3SoNKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=> NUL1[HYyOTd2OEW1NFE>
HEK293T NH\weHlCdnSrdnnyZYwhSXO|YYm= NHHlN2EyKG6P NHHvXmQ1KGR? NFfyRYpFVVOR NUT4T5hXUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGi0JJdqfGhiRVO1NEBw\iByLkOgcm0> NETmVZIyPzR6NUWwNS=>
PBMC M3ex[2Z2dmO2aX;uJGF{e2G7 MUexJI5O NU\tV41MOTRiZB?= NXTLZmFOTE2VTx?= MWTS[YR2[2W|IFPDVlUh\GWwc3n0fS=> NHfZOYcyPzR6NUWwNS=>
PBMC M33k[mZ2dmO2aX;uJGF{e2G7 M3v1U|Ehdk1? NG\L[IoyPCCm NFnhdnRFVVOR MoT3SI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> M3zWSFE4PDh3NUCx
HEK293 cells NEK3VWFMcW6jc3WgRZN{[Xl? M3LkXlUxKG6P MmHZOFUhdWmw NIDhUY1FVVOR MVPJcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5O MoXoNVc{PTB7NUO=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NF20c2JHfW6ldHnvckBCe3OjeR?= MVOxNFAhdk1? NHfMWnI1KGh? NV;aT5JXTE2VTx?= MVfJcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> NVmy[YVmOTdzMkiyOlI>
Human mixed lymphocyte NFHK[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXCUXE{PSCwTR?= NFvRNnlFVVOR NIPmeGtKSzVyPUGuOkBvVS5? MlvlNVYyQDV6NkW=
Lewis rat lymph node cells NYX3O3FjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;ZcFQ2KM7:TR?= M1\KWmROW09? M4L0dGlEPTB;Mj62JO69VQ>? MWOxOlE5PTh4NR?=
cells from the thymus of normal BALB/c mice NF34UW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T3XVExKG6P MVG3NkBp NFy4VZpFVVOR MY\Jcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P NHSxNm4yODB{MUm0PC=>
MRK-nu-1 NUW2cGo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULTXXBKUUN3ME2wMlg1PSCyTR?= NHj2cYRUSU6JRWK=
OCUB-M NWOxO2J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPtTWM2OD13LkK0JJBO NYfhPJpTW0GQR1XS
SF539 MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;kTWM2OD1zMT62JJBO NFHEOXlUSU6JRWK=
ES4 NEHtR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnNTWM2OD1{MT61JJBO MlLHV2FPT0WU
RL95-2 M3XqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfCVol{UUN3ME2xNFcheE1? NHzoT3RUSU6JRWK=
LC-2-ad NUSyTHhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;2WHlKSzVyPUSyN{BxVQ>? M4LRSHNCVkeHUh?=
Daudi MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zseGlEPTB;NEO0JJBO NHLrdohUSU6JRWK=
NTERA-S-cl-D1 NVG0RZhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XKVGlEPTB;NESzJJBO MnvmV2FPT0WU
OS-RC-2 NFrUfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LqN2lEPTB;NkWyJJBO NHTlXopUSU6JRWK=
VA-ES-BJ M1\yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTd{MzDwUS=> NVi5UVluW0GQR1XS
GR-ST M{XHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTh2NjDwUS=> MonKV2FPT0WU
SW872 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWe5UIs1UUN3ME24OFYheE1? NFG3OnNUSU6JRWK=
NOS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\EN4FKSzVyPUi3NUBxVQ>? NUTXdoFFW0GQR1XS
MC116 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSyPZVpUUN3ME25PFUheE1? NH\RTYlUSU6JRWK=
NCI-H1355 NYjWcIZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjmXndKSzVyPUGuNFEhdk1? MUjTRW5ITVJ?
RPMI-8226 MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DNbmlEPTB;MT6xPUBvVQ>? MnHuV2FPT0WU
TE-15 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnUNIJKSzVyPUGuN|Yhdk1? MoTRV2FPT0WU
Ramos-2G6-4C10 NVjZZXVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37qXGlEPTB;MT60OkBvVQ>? NHHmbolUSU6JRWK=
KU812 NIrmTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXETWM2OD1{LkCxJI5O NX3TUYlmW0GQR1XS
EW-1 NYK4NoxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJwMUegcm0> NWXY[m9uW0GQR1XS
KS-1 M4jR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPqSmZKSzVyPUKuOFUhdk1? Ml\kV2FPT0WU
SK-LMS-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS3dZBKSzVyPUKuOFkhdk1? NIDYWmNUSU6JRWK=
TGBC1TKB NXnQcFY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjhfJdNUUN3ME2yMlY6KG6P NHXuZoxUSU6JRWK=
TE-6 NE\4UndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nwVGlEPTB;Mj63O{BvVQ>? M1;lO3NCVkeHUh?=
ETK-1 NXzTPVlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnRVYhKSzVyPUKuPFIhdk1? NHT0cpJUSU6JRWK=
BE-13 M{m1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LZfmlEPTB;Mj65PUBvVQ>? MoTUV2FPT0WU
A3-KAW M3HwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVP5b|F1UUN3ME2yMlk6KG6P NWPMNFFTW0GQR1XS
TE-10 NITDZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n2fWlEPTB;Mz6zJI5O NFPjN45USU6JRWK=
DOHH-2 M2DvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTNwM{Wgcm0> Mn2zV2FPT0WU
ES6 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2noUmlEPTB;Mz60N{BvVQ>? NYrEcGZ3W0GQR1XS
OPM-2 NIG1OmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\q[G5[UUN3ME20MlE2KG6P NFXUO5VUSU6JRWK=
SH-4 NEPIO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoToTWM2OD12LkO0JI5O NXX0dFlFW0GQR1XS
NB13 NHjoZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrwTWM2OD12LkO2JI5O NYnRb2hPW0GQR1XS
HUTU-80 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LLTWlEPTB;ND60NkBvVQ>? MkO2V2FPT0WU
CCRF-CEM Mo\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fYW2lEPTB;ND65OEBvVQ>? MXzTRW5ITVJ?
TGBC24TKB NX;5PYRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTVwNUGgcm0> M1WxdXNCVkeHUh?=
697 NUfvXYF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;pXWlEPTB;Nj6yPEBvVQ>? NVe2V2ZoW0GQR1XS
J-RT3-T3-5 NFHmTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrCNJBKSzVyPU[uOFYhdk1? M1viWnNCVkeHUh?=
KALS-1 M1XZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKwUZVDUUN3ME22MlU3KG6P MWPTRW5ITVJ?
no-10 NH;WSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTdwMkmgcm0> MY\TRW5ITVJ?
SK-NEP-1 MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFKxc29KSzVyPUiuO|khdk1? M2fveHNCVkeHUh?=
L-540 MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fVW2lEPTB;MUCuOFIhdk1? MWLTRW5ITVJ?
JiyoyeP-2003 MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFyLkm0JI5O MnTMV2FPT0WU
HH MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[1TWM2OD1zMT6zPUBvVQ>? NX:1NJNRW0GQR1XS
SR NIjUWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFzLkS1JI5O MnrmV2FPT0WU
QIMR-WIL M4HoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPWe29KSzVyPUGxMlg2KG6P MoS5V2FPT0WU
A4-Fuk M{DveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF|LkGyJI5O MVrTRW5ITVJ?
CESS M3zwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIixb4tKSzVyPUGzMlE{KG6P Mn\SV2FPT0WU
KE-37 M2PnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj6XVlKSzVyPUG2MlA4KG6P MkHGV2FPT0WU
SK-UT-1 M1LFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXYdldKSzVyPUG2MlgyKG6P MVLTRW5ITVJ?
SIG-M5 MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33iPGlEPTB;MUeuNlUhdk1? M{DENXNCVkeHUh?=
HT M2\aZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3tW2VjUUN3ME2xO{43KG6P MofMV2FPT0WU
DEL MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHFT3BKSzVyPUG3Mlk6KG6P MlfqV2FPT0WU
SK-PN-DW NFP2eGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJyLkKzJI5O NUjITmM6W0GQR1XS
RPMI-8402 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPuXJAxUUN3ME2yNU44PyCwTR?= NI\1[3FUSU6JRWK=
RPMI-6666 M4PlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTUToZKSzVyPUK0MlQzKG6P MkLCV2FPT0WU
NCI-H720 M4LhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfmdGdIUUN3ME2yOU41OSCwTR?= NFz6dnNUSU6JRWK=
EW-16 NIX1S|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL3S5pKSzVyPUK2Mlg4KG6P NXHoOoRoW0GQR1XS
BL-70 MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJ6LkO4JI5O NGW4RnZUSU6JRWK=
SF126 NVvqV49ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX1dmlKSzVyPUOwMlM5KG6P MnSyV2FPT0WU
BC-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPvTWM2OD1|MT6yOkBvVQ>? NVXRXm5GW0GQR1XS
MHH-PREB-1 M{fYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7l[3A6UUN3ME2zNk41PCCwTR?= MUHTRW5ITVJ?
A101D MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTN{Lk[yJI5O MlWzV2FPT0WU
NMC-G1 NILVVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjzTFdKSzVyPUOzMlY4KG6P MmLBV2FPT0WU
LB1047-RCC MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTN2Lk[5JI5O MlW3V2FPT0WU
EM-2 NFXndnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv0[YVKSzVyPUO4MlU{KG6P MVPTRW5ITVJ?
COLO-684 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfyXnp7UUN3ME2zPU45KG6P NHfkSXFUSU6JRWK=
Becker NV3P[4VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HWOGlEPTB;NEGuNFUhdk1? NUG2U5BkW0GQR1XS
BL-41 M3jPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv2TWM2OD12Mz62OkBvVQ>? Mo\MV2FPT0WU
MDA-MB-134-VI M2nQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS2TWM2OD12ND6wNkBvVQ>? NUDLOVhpW0GQR1XS
L-363 Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrMZpRwUUN3ME20OE44OyCwTR?= MmftV2FPT0WU
ECC4 MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7peGNlUUN3ME20OE44QCCwTR?= NYTUbJNOW0GQR1XS
A388 NUnuZYtLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTR2LkiyJI5O NU[wVnpjW0GQR1XS
HEL M3XMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M324cmlEPTB;NEmuO|khdk1? M1XhUXNCVkeHUh?=
RKO MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHpTWM2OD13MD6yPUBvVQ>? NIjHO5RUSU6JRWK=
KINGS-1 M4\YNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jJVmlEPTB;NUGuOVUhdk1? NV7GfHdoW0GQR1XS
EB-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPtSYZDUUN3ME21Nk43PyCwTR?= MmPWV2FPT0WU
ARH-77 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf4V2JKSzVyPUWyMlghdk1? NG[2cnZUSU6JRWK=
GCIY MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTV|LkS2JI5O M{L1b3NCVkeHUh?=
NCI-H1304 NV\yNXJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTV5LkKyJI5O M33oNHNCVkeHUh?=
KARPAS-299 M4TINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[yV2NpUUN3ME22NU45OiCwTR?= MWnTRW5ITVJ?
IA-LM M2nvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITLWFdKSzVyPU[4MlE{KG6P NW\wcpNJW0GQR1XS
GI-1 NWriXVRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPQfJJrUUN3ME23NE4{QSCwTR?= NUj1fHFRW0GQR1XS
TE-11 NX;B[IJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny3TWM2OD15Nz6xO{BvVQ>? M1uyPXNCVkeHUh?=
LS-411N M{LsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTd5LkW3JI5O MmS3V2FPT0WU
no-11 NGXEOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTh|LkK0JI5O M{HmcXNCVkeHUh?=
MV-4-11 NXS2RmpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTBWHVKSzVyPUizMlc{KG6P M3rkZXNCVkeHUh?=
BV-173 NFLkRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTh|Lkm3JI5O M2HXN3NCVkeHUh?=
CMK M37vbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnQeFFKSzVyPUi0MlE3KG6P MU\TRW5ITVJ?
LC4-1 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnT[oZxUUN3ME24Ok44OiCwTR?= M3q2ZXNCVkeHUh?=
COR-L279 MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jt[mlEPTB;OEeuNlUhdk1? MVzTRW5ITVJ?
NCI-H209 NHjD[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TIO2lEPTB;OEeuOFEhdk1? NFn0U3hUSU6JRWK=
Raji NH;zNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\o[olKSzVyPUi5MlczKG6P NIPXd2FUSU6JRWK=
LB996-RCC M{jjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnn[nBSUUN3ME25N{41OyCwTR?= NInnbIxUSU6JRWK=
NCI-H526 NIrqcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TnbGlEPTB;OUOuOVkhdk1? MUDTRW5ITVJ?
KGN MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv3TWM2OD17Nj6yPUBvVQ>? M3f6UnNCVkeHUh?=
MOLT-4 MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7CNIxxUUN3ME25Ok44QSCwTR?= MV\TRW5ITVJ?
PF-382 NFHwVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrYV|JlUUN3ME25Ok44QSCwTR?= NFnBcYxUSU6JRWK=
BC-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjGfYtKSzVyPUm5MlE5KG6P MmfoV2FPT0WU
KARPAS-422 M{\SXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIji[HRKSzVyPUGwNk4xQSCwTR?= MkTyV2FPT0WU
SBC-1 MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TH[WlEPTB;MUC3Mlc2KG6P NGj5XG1USU6JRWK=
LC-1F M2rBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\nTWM2OD1zMEiuNFUhdk1? M2LBTXNCVkeHUh?=
GB-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW4WYpKSzVyPUGwPU4xOiCwTR?= MVXTRW5ITVJ?
SNB75 MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrZWGxQUUN3ME2xNVkvPjlibl2= M1TUNnNCVkeHUh?=
BB65-RCC NULnPVZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C3SmlEPTB;MUG5Mlk{KG6P MWLTRW5ITVJ?
NCI-N87 NXvTOXFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlflTWM2OD1zMkGuPVghdk1? MorQV2FPT0WU
IST-MEL1 M37NXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPBTWM2OD1zMkKuN|ghdk1? M2nBXXNCVkeHUh?=
HOP-62 NY\TdZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF{Nj64PUBvVQ>? MnjrV2FPT0WU
ACN NVr1[|c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrae2xKSzVyPUG0Ok44PSCwTR?= NFPUWIxUSU6JRWK=
DMS-114 NXn5cm5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfFO4dKSzVyPUG1NE43PyCwTR?= M4j0VXNCVkeHUh?=
MLMA NV\k[oRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF3OT64PEBvVQ>? NVy5XWJ3W0GQR1XS
HT-144 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoGzTWM2OD1zNkWuOFMhdk1? MnjZV2FPT0WU
C2BBe1 M3K2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC0bXk5UUN3ME2xOlcvPzZibl2= Moq2V2FPT0WU
L-428 M1frd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF5Nz63JI5O NXK1[JhIW0GQR1XS
DU-4475 M1nCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF6Nz62PEBvVQ>? MVPTRW5ITVJ?
CP67-MEL M3XiSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTF7OT6zPEBvVQ>? NXnxNm9SW0GQR1XS
MEG-01 NGnkPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofPTWM2OD1{MEGuPVYhdk1? NEHS[ppUSU6JRWK=
IST-SL2 MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfZN|JKSzVyPUKwPE43OyCwTR?= MU\TRW5ITVJ?
ES8 NH3tOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJ{NT65OEBvVQ>? M4\DcXNCVkeHUh?=
COLO-800 M4TZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJ|NT6yPEBvVQ>? Mk[wV2FPT0WU
MFH-ino NXGxfWZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJ|NT64OEBvVQ>? MnzKV2FPT0WU
OVCAR-4 NUHkWYJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXTNnpWUUN3ME2yN|cvOjRibl2= MnLXV2FPT0WU
PSN1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIewbodKSzVyPUK0Nk44OSCwTR?= MXrTRW5ITVJ?
EW-12 NF;tPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDZTWM2OD1{NEOuNUBvVQ>? NV3LdG1VW0GQR1XS
HCC1599 NF\BN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn0TWM2OD1{NkGuOFchdk1? M1PL[nNCVkeHUh?=
SJSA-1 M2rDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f6T2lEPTB;MkexMlQ3KG6P MX;TRW5ITVJ?
ST486 Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXpU2dKSzVyPUK5Ok4yPCCwTR?= NXXXSHQ6W0GQR1XS
NOMO-1 NGDmUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvBdplVUUN3ME2zNFAvOjFibl2= M1PFeHNCVkeHUh?=
MN-60 NFvHRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjRTWM2OD1|MEWuN|Ihdk1? MmPzV2FPT0WU
HCC1187 NVHrdHpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNyNz6yOUBvVQ>? M3;PbXNCVkeHUh?=
SW982 M132bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTNzND63OUBvVQ>? M1PEWXNCVkeHUh?=
LB647-SCLC NFfre|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[1VlBKSzVyPUOyPE44OSCwTR?= MnjKV2FPT0WU
HC-1 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD4TWM2OD1|M{WuOUBvVQ>? NFTOTVhUSU6JRWK=
EHEB MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO0TWM2OD1|M{euOVIhdk1? MlnmV2FPT0WU
TUR M4TWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnQdGl4UUN3ME2zOlMvQTVibl2= NULXUpQ{W0GQR1XS
LU-139 NFP4b4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTN5OD6wNkBvVQ>? NXq1[nc4W0GQR1XS
NB1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T1cGlEPTB;M{i0MlQ2KG6P NIPRdHFUSU6JRWK=
BB30-HNC M{jqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHQWXJKSzVyPUO4PE4{OiCwTR?= NE[3SYxUSU6JRWK=
HAL-01 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTN6OT6yOkBvVQ>? NFH5NmlUSU6JRWK=
K5 NUjTR4Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTRzMT6zO{BvVQ>? M{[1WHNCVkeHUh?=
MZ2-MEL Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTRzMz62OEBvVQ>? Ml:wV2FPT0WU
RXF393 M1TIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTRzNj60OUBvVQ>? MlfLV2FPT0WU
NCI-H1648 NIjDNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTL[|Y1UUN3ME20NVcvPTNibl2= M4DxR3NCVkeHUh?=
TE-12 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPnVmlkUUN3ME20N|QvOjZibl2= NYC1OY04W0GQR1XS
EoL-1- NXTP[G1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX0TWM2OD12M{euPVghdk1? NH7KcFRUSU6JRWK=
JAR NWPUUXhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGybo1vUUN3ME20N|gvPjJibl2= MVPTRW5ITVJ?
DSH1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi0[m1KSzVyPUS1PE46OSCwTR?= MnnkV2FPT0WU
NCI-H187 M3fDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTR4Mj64NUBvVQ>? MYTTRW5ITVJ?
HCE-4 NGC3cpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfyenQ6UUN3ME20O|cvPjZibl2= MVPTRW5ITVJ?
8-MG-BA MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLlTWM2OD13OEGuOVIhdk1? MUTTRW5ITVJ?
KLE NX\nUZRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHYWlBPUUN3ME21PFUvOiCwTR?= M3nOVnNCVkeHUh?=
KNS-42 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;sZ21SUUN3ME21PFYvQDFibl2= NUDUN|RoW0GQR1XS
MSTO-211H NHvndHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjHOJBJUUN3ME22NFkvPzRibl2= MVLTRW5ITVJ?
GDM-1 NH3Wc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL2TWM2OD14MUSuNFkhdk1? NH3pTlRUSU6JRWK=
TE-1 MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HseWlEPTB;NkS2MlEzKG6P NEPKUoZUSU6JRWK=
BT-474 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHHTWM2OD14NEeuNFYhdk1? NWqzWHpHW0GQR1XS
KARPAS-45 M4O5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf3foxjUUN3ME22OFcvPiCwTR?= MljjV2FPT0WU
MOLT-16 NEXhUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfkbYJxUUN3ME22OFcvQTNibl2= MUPTRW5ITVJ?
KURAMOCHI NVrhV4hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M16yZ2lEPTB;NkW3MlUyKG6P NXz6[GdSW0GQR1XS
K-562 M13SVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\MTWM2OD14NkmuOVEhdk1? NHXqfWpUSU6JRWK=
EKVX NWjIRXIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPRTWM2OD14N{KuO|Ehdk1? MnTmV2FPT0WU
GAK MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfZbJBKUUN3ME22O|UvOyCwTR?= Mkm4V2FPT0WU
NCI-SNU-5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTZ7MD6wNUBvVQ>? M1Tu[XNCVkeHUh?=
NCI-H2126 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvCTWM2OD15Mk[uPFchdk1? MnTxV2FPT0WU
CTV-1 Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITrUpFKSzVyPUe0OE46KG6P M4G5S3NCVkeHUh?=
SW962 MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnQTWM2OD15NEiuOFQhdk1? MoLnV2FPT0WU
MONO-MAC-6 NV7XOYo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7XS3hKSzVyPUe1Ok46OyCwTR?= M{i3NnNCVkeHUh?=
NCI-H748 M1fBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTd3OD65PUBvVQ>? M33kZnNCVkeHUh?=
NCI-H524 MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3hTWM2OD15OECuO|Mhdk1? NGTFeldUSU6JRWK=
LS-123 M{TPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjsTWM2OD15OUWuOlkhdk1? NUfGNVlwW0GQR1XS
NB7 M4XsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXBdJBKSzVyPUixOE4yPCCwTR?= NHftOWRUSU6JRWK=
LS-1034 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HFfGlEPTB;OEK4Mlk5KG6P NVnuXYc1W0GQR1XS
TE-5 M{DPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTh6Mz61OkBvVQ>? NWq0c4lCW0GQR1XS
A704 NFvSWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTh7OT6xOUBvVQ>? NUPIPZJCW0GQR1XS
TK10 M3\qcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnEVlhPUUN3ME25NVYvODNibl2= NV;iPFdHW0GQR1XS
NCI-H345 MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTOfFZKSzVyPUm0N{4zOiCwTR?= NGCyTGtUSU6JRWK=
CGTH-W-1 M3XNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXITWM2OD17NEiuNVMhdk1? MYLTRW5ITVJ?
NCI-H510A M{HFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLUTZJsUUN3ME25PFUvOTJibl2= MkXFV2FPT0WU
NCI-H1963 M2\GXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmriTWM2OD1zLkCzNlkzKM7:TR?= M4jiWnNCVkeHUh?=
SCC-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETlTFdKSzVyPUGuNFM1OTRizszN MmrwV2FPT0WU
EW-11 MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFwMEi3OFMh|ryP NEjPfFRUSU6JRWK=
CPC-N MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFwMEi4JO69VQ>? M2nXV3NCVkeHUh?=
NCI-H1417 MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[x[mNKSzVyPUGuNVIzPiEQvF2= MWLTRW5ITVJ?
DG-75 MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvLTWM2OD1zLkG2Nlg2KM7:TR?= MmDuV2FPT0WU
HD-MY-Z MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LNcmlEPTB;MT6xOlQyPiEQvF2= NX2zZoRyW0GQR1XS
ATN-1 M1vLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTFwMk[yNFkh|ryP NXHY[2w5W0GQR1XS
KM-H2 NEPGeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HXZWlEPTB;MT6yOlQxQCEQvF2= MVjTRW5ITVJ?
NCI-H2081 M2Lk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHnPHVrUUN3ME2xMlI3PjN5IN88US=> MmTCV2FPT0WU
HL-60 M4PDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFwMk[5OVkh|ryP MXXTRW5ITVJ?
DB M4K5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTtTWM2OD1zLkK3NlQzKM7:TR?= NFTacpRUSU6JRWK=
NCI-H1522 NFjPfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PwR2lEPTB;MT6yPFg5PyEQvF2= NEG4VWpUSU6JRWK=
AM-38 NUHROWEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwM{C3NkDPxE1? MWrTRW5ITVJ?
NCI-H446 MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\ZTWM2OD1zLkOyNVIyKM7:TR?= NFjnWFVUSU6JRWK=
SU-DHL-1 MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjYTWM2OD1zLkOyPFAyKM7:TR?= NFzte4hUSU6JRWK=
NH-12 NHzFemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLGTWM2OD1zLkO2N|c1KM7:TR?= MUPTRW5ITVJ?
DMS-79 MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3lTWM2OD1zLkO2PFY3KM7:TR?= M1vSTXNCVkeHUh?=
NCI-H716 MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFwM{i5PFYh|ryP MmHUV2FPT0WU
ML-2 Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTPU2pKSzVyPUGuOFE2OjlizszN NFPLOZhUSU6JRWK=
NB10 M4rsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTFwNE[2N|Ih|ryP MnTJV2FPT0WU
ONS-76 NH7FW|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFwNUO1Olkh|ryP NFzkc5hUSU6JRWK=
LOUCY NFTsc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFwNUS2OVch|ryP M4\LOXNCVkeHUh?=
SCLC-21H MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2i2fmlEPTB;MT61PFU5OiEQvF2= NH3YeFBUSU6JRWK=
TGW Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTxTWM2OD1zLk[zPVc2KM7:TR?= M37U[XNCVkeHUh?=
LXF-289 NHjNdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXXVG5qUUN3ME2xMlc{OjZ6IN88US=> Ml\2V2FPT0WU
BB49-HNC MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfWNopKSzVyPUGuO|M2QDZizszN MX\TRW5ITVJ?
NCI-H747 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkexTWM2OD1zLke1N|Q3KM7:TR?= M1nZeHNCVkeHUh?=
LU-165 NGrUT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LxS2lEPTB;MT64OFk5PiEQvF2= MXHTRW5ITVJ?
OMC-1 NHLxd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX5b4FKSzVyPUGuPVUxPjZizszN NVfSUJBMW0GQR1XS
RCC10RGB NVXlUm5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn6[|ZQUUN3ME2xMlk2QDF5IN88US=> MlzQV2FPT0WU
SW684 Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFwOU[wPVkh|ryP MorPV2FPT0WU
TE-8 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJwMEW1OVkh|ryP MV\TRW5ITVJ?
SK-N-DZ NXjWNnF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nRdWlEPTB;Mj6xN|I4PCEQvF2= MljDV2FPT0WU
EVSA-T MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTqNZoyUUN3ME2yMlE4OzF3IN88US=> MYjTRW5ITVJ?
KASUMI-1 NUXGTHR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHmVHhKSzVyPUKuNVg5OTVizszN M{\xeHNCVkeHUh?=
NKM-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXlblFKSzVyPUKuNlU1PzJizszN NEHRRoxUSU6JRWK=
CAL-148 NYrtOoNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvTTWM2OD1{LkOzOlE1KM7:TR?= NYG1VWF6W0GQR1XS
NCI-H64 MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJwM{SyN|Ih|ryP NGnHZ4dUSU6JRWK=
KNS-81-FD MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXUfW5FUUN3ME2yMlM3PjJizszN MWrTRW5ITVJ?
KM12 NFPsSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHtTWM2OD1{LkSwPFM6KM7:TR?= NHTRcppUSU6JRWK=
SW954 M3rafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLRWJIyUUN3ME2yMlQ4Pzd7IN88US=> MW\TRW5ITVJ?
NCI-H1395 NVXVdIRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnHZVlKSzVyPUKuOVI3PDVizszN NYSy[2FMW0GQR1XS
DJM-1 NFHv[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljOTWM2OD1{Lk[wOlMh|ryP NXPPc|hXW0GQR1XS
COLO-668 M3jUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml23TWM2OD1{LkiyOlk2KM7:TR?= NF:3PI9USU6JRWK=
NCI-H1436 M3fsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJwOEW2NVUh|ryP MXzTRW5ITVJ?
LB2241-RCC NVW2WmxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXGTWM2OD1{Lki2PFM6KM7:TR?= NVTkUmtbW0GQR1XS
GT3TKB NYr4SHk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33WWWlEPTB;Mj64PVA2PSEQvF2= M{ixd3NCVkeHUh?=
COLO-824 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJwOEm3Olgh|ryP MmnxV2FPT0WU
ES1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHUTWM2OD1{Lki5PFc6KM7:TR?= NI[zW45USU6JRWK=
LB771-HNC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rJRWlEPTB;Mj65NFk1PiEQvF2= MmXvV2FPT0WU
GI-ME-N MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXrXZRKSzVyPUOuNFA6ODRizszN M2f1bnNCVkeHUh?=
NALM-6 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HOfmlEPTB;Mz6wNFk{OyEQvF2= NH3rWmZUSU6JRWK=
LU-134-A MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHuTWM2OD1|LkC1OFI2KM7:TR?= NVzUNVMxW0GQR1XS
DMS-153 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjRNmtKSzVyPUOuNFU5OjRizszN NF\wT2ZUSU6JRWK=
MZ1-PC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvmTWM2OD1|LkC5NFc5KM7:TR?= NYHk[lN2W0GQR1XS
NCI-H1155 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqzTWM2OD1|LkGxOlEh|ryP NGPZUZlUSU6JRWK=
CAS-1 M2TpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;qTWM2OD1|LkGzO|A4KM7:TR?= NXH1ZpAzW0GQR1XS
D-502MG NXfLU45JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTNwMUSzPUDPxE1? NWq0VpRNW0GQR1XS
NCI-H2141 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm0TWM2OD1|LkG3OFUzKM7:TR?= NUjTPJNMW0GQR1XS
NB6 M{\0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTNwMUiyOVkh|ryP NXXYOZBYW0GQR1XS
NCCIT NWr2N5o6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTNwMkG4NFkh|ryP MmXBV2FPT0WU
NB69 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33UdWlEPTB;Mz6zNVg6OSEQvF2= M{DhWnNCVkeHUh?=
JVM-2 NYL2TZZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfnTWM2OD1|LkO2OFM{KM7:TR?= M4nz[nNCVkeHUh?=
K052 NHq3U5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTNwM{e5Olgh|ryP NYTCcFNsW0GQR1XS
HCC2157 M3;MWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTNwNUOyNlgh|ryP NYXIVGc1W0GQR1XS
KMOE-2 NYG1UYNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTNwNUSyOFIh|ryP M4\qTXNCVkeHUh?=
SF268 NIfZV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnxdo5kUUN3ME2zMlcyPTV2IN88US=> M4TFNHNCVkeHUh?=
CHP-126 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[5TWM2OD1|Lke2OFU5KM7:TR?= M1G5NnNCVkeHUh?=
CP66-MEL MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrOTnpYUUN3ME2zMlc6ODl2IN88US=> Ml7FV2FPT0WU
NCI-H69 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\VUlJ{UUN3ME20MlAyQTN4IN88US=> M2rvd3NCVkeHUh?=
A253 M2Ptdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjHTWM2OD12LkCyNVAyKM7:TR?= MXrTRW5ITVJ?
NB14 NEDYXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIriSHhKSzVyPUSuNVA1PzlizszN MXvTRW5ITVJ?
NCI-H1694 NGW5RnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfCSVJKSzVyPUSuNVMyOTJizszN NHLJdllUSU6JRWK=
NCI-H2196 NID3NG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTRwMUexOlkh|ryP MkLXV2FPT0WU
TE-9 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j5fmlEPTB;ND6xO|U5OiEQvF2= NH3LcpRUSU6JRWK=
D-283MED NGPM[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnOTWM2OD12LkG4PFQh|ryP MXvTRW5ITVJ?
OCI-AML2 NEW4UGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\JWmlEPTB;ND6xPVQ5QSEQvF2= MmPXV2FPT0WU
D-263MG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnzTWM2OD12LkKyPVYyKM7:TR?= NFnLRYFUSU6JRWK=
MPP-89 MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP5TWM2OD12LkK3N|A1KM7:TR?= NEjo[FBUSU6JRWK=
LAMA-84 M13Sfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTRwM{C0NlEh|ryP NHPMS|NUSU6JRWK=
LB373-MEL-D NGPpb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nlemlEPTB;ND6zOlc5QSEQvF2= MVzTRW5ITVJ?
UACC-257 M2TLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zScWlEPTB;ND6zPVU{PCEQvF2= M2nwd3NCVkeHUh?=
MC-CAR NXPSc29pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTRwNEO5PUDPxE1? NFfud45USU6JRWK=
COLO-320-HSR NWjCe3AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmxTWM2OD12LkS0OFI4KM7:TR?= M1jGPXNCVkeHUh?=
P30-OHK MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHCOnJKSzVyPUSuOlY2QDFizszN MkGyV2FPT0WU
UACC-812 MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPweGhKSzVyPUSuOlkyPjFizszN NFLIN49USU6JRWK=
CTB-1 MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LpeWlEPTB;ND63NVU2PSEQvF2= NF;MbGtUSU6JRWK=
ALL-PO M{DOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofMTWM2OD12Lki0NFc4KM7:TR?= M1TXR3NCVkeHUh?=
SK-MEL-2 NFjUTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LUTmlEPTB;ND64Olk2PSEQvF2= NIXMUJdUSU6JRWK=
TC-YIK Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzMTWM2OD12Lkm3PVQzKM7:TR?= NVjCNWZiW0GQR1XS
NCI-H1882 NU[1N25[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLkTWM2OD13LkCyNFAyKM7:TR?= M4XFTHNCVkeHUh?=
MHH-CALL-2 M{flfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzSTFFKSzVyPUWuNFUxPDJizszN MmDZV2FPT0WU
U-87-MG MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTVwMEm0OlYh|ryP M{C3R3NCVkeHUh?=
NCI-H1092 M3TGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3L1SWlEPTB;NT6yOlU2PSEQvF2= NYrkcGZiW0GQR1XS
TE-441-T NXnzcmo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M363WWlEPTB;NT6yO|gzKM7:TR?= M1vuWHNCVkeHUh?=
SK-MEL-1 M4LHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme0TWM2OD13LkK5NFQ1KM7:TR?= Mlu5V2FPT0WU
EW-22 NWDPO5ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn6TWM2OD13LkK5OFY3KM7:TR?= Mn\KV2FPT0WU
MZ7-mel M3rtbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W5XmlEPTB;NT60NFY6OSEQvF2= NWHyUFBLW0GQR1XS
LP-1 M13Nc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC1TWM2OD13LkSxNlkyKM7:TR?= Mli0V2FPT0WU
NCI-SNU-16 M1v6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3WbY5KSzVyPUWuOlQxPzRizszN MWLTRW5ITVJ?
LU-65 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTVwN{[zO|Mh|ryP NHTXTGFUSU6JRWK=
CW-2 NWXTPFQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPlTWM2OD13Lki1PVU6KM7:TR?= NHnhNo1USU6JRWK=
WSU-NHL NGTZSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHpdVVMUUN3ME21Mlk2OTd2IN88US=> Mle0V2FPT0WU
IST-MES1 NIDyT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD2XlNKSzVyPUWuPVU1PDNizszN NVznN2d5W0GQR1XS
U-266 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Xsb2lEPTB;NT65PFIxOiEQvF2= NGrnT3hUSU6JRWK=
TALL-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTZwMUS2PFgh|ryP NYP1VIdqW0GQR1XS
Calu-6 MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M334XWlEPTB;Nj6xOVMyPiEQvF2= M2Xzc3NCVkeHUh?=
MMAC-SF NXy3VoFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDXTWM2OD14LkG4OVU3KM7:TR?= M{LHdHNCVkeHUh?=
NCI-H82 NXL4NXJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrWTWM2OD14LkKwOFg6KM7:TR?= NYDKV3pkW0GQR1XS
RS4-11 NVe4d3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TiZ2lEPTB;Nj6yOVg6PyEQvF2= MkLQV2FPT0WU
SNU-C2B NHHwdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L5SmlEPTB;Nj60NFk3QSEQvF2= NWDrWXpZW0GQR1XS
BOKU MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rsVmlEPTB;Nj60O|U6PyEQvF2= MkDWV2FPT0WU
C8166 M4rD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LUU2lEPTB;Nj61OVkyOiEQvF2= MljpV2FPT0WU
D-247MG MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXztWIY1UUN3ME23MlA1OzR5IN88US=> M37WRnNCVkeHUh?=
EW-18 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVewSm57UUN3ME23MlA4Ojl{IN88US=> MnPSV2FPT0WU
KG-1 Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTdwNkK3N|gh|ryP NHmzWpFUSU6JRWK=
REH MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfGN|lKSzVyPUeuOlgyODlizszN M2ThdXNCVkeHUh?=
U-698-M NHXtdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDGWY1KSzVyPUeuPFQ{OTVizszN NGrLfmJUSU6JRWK=
KP-N-RT-BM-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\6dVJKSzVyPUeuPVMxOjlizszN NWSw[29xW0GQR1XS
MS-1 M2X6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\lTFF{UUN3ME23Mlk3ODRzIN88US=> NWjaR2pXW0GQR1XS
SNU-C1 NITlTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHZeoFKSzVyPUeuPVgyQTJizszN NWDicm9DW0GQR1XS
SK-MM-2 MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRThwMk[wOlUh|ryP NHPQSFNUSU6JRWK=
LAN-6 Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jXd2lEPTB;OD6zNFAxOSEQvF2= NX3lSXNoW0GQR1XS
NEC8 NGrvUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrnTWM2OD16LkOwOlkyKM7:TR?= NXTReJhQW0GQR1XS
NCI-H1770 NWfMV3c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLKe|hKSzVyPUiuN|gxODJizszN Ml76V2FPT0WU
D-336MG NV\pVIxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRThwNECxNVYh|ryP NVjTWYw6W0GQR1XS
COLO-829 NInh[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7yOY1KSzVyPUiuOFg5PzlizszN MnfGV2FPT0WU
LS-513 M2W5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW3TWM2OD16LkW5OVk6KM7:TR?= MXHTRW5ITVJ?
YT MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXmTWM2OD16Lk[yOFI4KM7:TR?= NWe3PIl1W0GQR1XS
EW-24 NILyd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDzTWM2OD16Lke2OVQh|ryP MoLJV2FPT0WU
IST-SL1 NUPm[5ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LudWlEPTB;OD64OlU1OyEQvF2= M3;Gd3NCVkeHUh?=
CA46 M4LlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVi0WJRGUUN3ME24Mlk2ODl6IN88US=> MULTRW5ITVJ?
NCI-H1838 NIjqdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRThwOUi2NFIh|ryP MV7TRW5ITVJ?
NCI-H719 NFrNVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTlwMkWyO|kh|ryP NVXTXpFGW0GQR1XS
HCE-T M4HPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PGPGlEPTB;OT6zNFg2OSEQvF2= NWfRZnA4W0GQR1XS
A498 NFqzbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILoRpJKSzVyPUmuN|YyOjRizszN NFiycXlUSU6JRWK=
LB831-BLC MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\Qd4xNUUN3ME25Mlc3PTJzIN88US=> NHHMe4NUSU6JRWK=
SKM-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPuR25iUUN3ME25Mlg2QTZ|IN88US=> MWTTRW5ITVJ?
THP-1 Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3MXmtTUUN3ME25Mlk3QTF6IN88US=> MmrvV2FPT0WU
SHP-77 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHEN|ZKSzVyPUGwMlQxPyEQvF2= M1e5PXNCVkeHUh?=
EW-3 MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HSV2lEPTB;MUCuOlI5QSEQvF2= MYfTRW5ITVJ?
KY821 M4P4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;yTWM2OD1zMD63OlMh|ryP Ml;RV2FPT0WU
NCI-SNU-1 NIDTWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\HTWM2OD1zMT6wNlE4KM7:TR?= NEHyVXZUSU6JRWK=
HCC2218 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFzLkO5PFYh|ryP MknkV2FPT0WU
IM-9 M{e2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrx[ohKSzVyPUGxMlUyODZizszN NUfab|N{W0GQR1XS
NCI-H889 MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;Hb2lEPTB;MUGuOVMyOyEQvF2= MX7TRW5ITVJ?
HDLM-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDSemxnUUN3ME2xNk41OTV7IN88US=> NIj0dWpUSU6JRWK=
LB2518-MEL MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD0WXVUUUN3ME2xNk43QDF3IN88US=> M33sbHNCVkeHUh?=
NCI-H23 NEXWVmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\hZmlEPTB;MUOuNlQzPSEQvF2= NVj3bWxNW0GQR1XS
NB17 NG\aZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Hl[WlEPTB;MUOuOFU4QSEQvF2= MXLTRW5ITVJ?
NCI-H322M M4[yVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF2LkSwOlgh|ryP NF\Fc|lUSU6JRWK=
SUP-T1 Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HteWlEPTB;MUSuOFE{KM7:TR?= MojVV2FPT0WU
ES3 M1vnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF3LkC3NFMh|ryP MXHTRW5ITVJ?
ES5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF3LkC3PFch|ryP NWHFTVRSW0GQR1XS
NCI-H1650 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLpPHZNUUN3ME2xOU41QTd7IN88US=> M33HeXNCVkeHUh?=
NCI-H226 M3jzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ewXmlEPTB;MUWuPFc3QCEQvF2= M3e3W3NCVkeHUh?=
COR-L88 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi2cY9KSzVyPUG2MlMyPCEQvF2= M3n1dnNCVkeHUh?=
SCC-15 NXn5RnRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\jdlRKSzVyPUG2MlM5PjlizszN MoP1V2FPT0WU
GOTO NIfaUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SxbmlEPTB;MU[uOFc6OyEQvF2= NXu1RmRTW0GQR1XS
SIMA MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HVXWlEPTB;MU[uOFgxOiEQvF2= NHTC[m9USU6JRWK=
NCI-H1299 M332N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF5LkG1PVEh|ryP M3rjeHNCVkeHUh?=
NCI-H1581 Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T2XGlEPTB;MUeuOFIyQSEQvF2= MV\TRW5ITVJ?
MHH-NB-11 M4fjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;Vc2lEPTB;MUeuPVY5OyEQvF2= Mn7UV2FPT0WU
MFM-223 MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3njO2lEPTB;MUiuNFU{QCEQvF2= NUn6R2pQW0GQR1XS
ES7 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHubmk{UUN3ME2xPE42PDNzIN88US=> M2DYXXNCVkeHUh?=
JVM-3 M{PvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn5eJZKSzVyPUG4MlcyPyEQvF2= M3[2bnNCVkeHUh?=
RL NEHsc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLMTWM2OD1{MD6zPFgh|ryP M3n5WXNCVkeHUh?=
EC-GI-10 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLsfpNuUUN3ME2yNU4zODRzIN88US=> M3PUVnNCVkeHUh?=
LNCaP-Clone-FGC NELVOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{noSGlEPTB;MkGuOlc3QCEQvF2= NHPiSG1USU6JRWK=
IMR-5 Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:ybmlEPTB;MkGuPFQ6PCEQvF2= MWHTRW5ITVJ?
KP-N-YS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJzLki3OUDPxE1? NXL3NFdkW0GQR1XS
Mo-T MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJ{LkKxPFUh|ryP M2TvcHNCVkeHUh?=
NCI-H128 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlewTWM2OD1{Mz61PFU{KM7:TR?= MVHTRW5ITVJ?
RH-1 NHjje3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJ|Lke4OlYh|ryP M3LYenNCVkeHUh?=
NCI-H2171 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXGTmRKSzVyPUK0MlI1QDVizszN NITsOG9USU6JRWK=
RPMI-8866 NEDWXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnuV4JKSzVyPUK2Mlc1OiEQvF2= MnTFV2FPT0WU
SK-N-FI MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LobGlEPTB;MkeuN|gyOSEQvF2= NH7XO|hUSU6JRWK=
LOXIMVI NWXCO2I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorzTWM2OD1{Nz64NFUyKM7:TR?= NYnZPVFyW0GQR1XS
P31-FUJ NEKzS4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TWOGlEPTB;M{GuOVM4PCEQvF2= Mn3XV2FPT0WU
KMS-12-PE NVXNVFJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnmNVN{UUN3ME20PU42OzB{IN88US=> NHO0bHZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03866681 Not yet recruiting Paroxysmal Nocturnal Hemoglobinuria Peking Union Medical College Hospital April 1 2019 Phase 4
NCT03454724 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. April 1 2019 Not Applicable
NCT03877809 Not yet recruiting Beta-Thalassemia Rare Partners srl Impresa Sociale|Università degli Studi di Ferrara April 1 2019 Phase 2
NCT03866681 Not yet recruiting Paroxysmal Nocturnal Hemoglobinuria Peking Union Medical College Hospital April 1 2019 Phase 4
NCT03454724 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. April 1 2019 Not Applicable
NCT03877809 Not yet recruiting Beta-Thalassemia Rare Partners srl Impresa Sociale|Università degli Studi di Ferrara April 1 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID